{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:32:44Z","timestamp":1740123164983,"version":"3.37.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T00:00:00Z","timestamp":1699056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11033-023-08832-4","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T10:01:32Z","timestamp":1699092092000},"page":"10157-10167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells"],"prefix":"10.1007","volume":"50","author":[{"given":"Sara","family":"Zehtabcheh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir-Mohammad","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Momeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5998-1722","authenticated-orcid":false,"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,4]]},"reference":[{"key":"8832_CR1","doi-asserted-by":"crossref","unstructured":"Goldman JM (ed) (2010) Editor chronic myeloid leukemia: a historical perspective. Seminars in hematology. Elsevier","DOI":"10.1053\/j.seminhematol.2010.07.001"},{"issue":"2","key":"8832_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2141.2006.06161.x","volume":"134","author":"P Coppo","year":"2006","unstructured":"Coppo P, Flamant S, Mas VD, Jarrier P, Guillier M, Bonnet ML, Lacout C, Guilhot F, Vainchenker W, Turhan AG (2006) BCR\u2013ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 134(2):171\u2013179","journal-title":"Br J Haematol"},{"issue":"5","key":"8832_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/cgt.2014.65","volume":"22","author":"Q Li","year":"2015","unstructured":"Li Q, Wu Y, Fang S, Wang L, Qi H, Zhang Y, Zhang J, Li W (2015) BCR\/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing the immuno-modulatory function of hemangioblasts. Cancer Gene Ther 22(5):227\u2013237","journal-title":"Cancer Gene Ther"},{"key":"8832_CR4","unstructured":"Szeto M (2017) Mechanisms of RAS\/MAPK signaling by BCR-ABL1 in chronic myeloid leukemia. UCSF"},{"issue":"24","key":"8832_CR5","doi-asserted-by":"publisher","first-page":"8939","DOI":"10.1158\/0008-5472.CAN-04-0981","volume":"64","author":"T Mihailovic","year":"2004","unstructured":"Mihailovic T, Marx M, Auer A, Van Lint J, Schmid M, Weber C, Seufferlein T (2004) Protein kinase D2 mediates activation of nuclear factor \u03baB by bcr-abl in bcr-abl + human myeloid leukemia cells. Cancer Res 64(24):8939\u20138944","journal-title":"Cancer Res"},{"issue":"14","key":"8832_CR6","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.3390\/cancers14143300","volume":"14","author":"G Poudel","year":"2022","unstructured":"Poudel G, Tolland MG, Hughes TP, Pagani IS (2022) Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers 14(14):3300","journal-title":"Cancers"},{"issue":"5","key":"8832_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cbin.11557","volume":"45","author":"S Zehtabcheh","year":"2021","unstructured":"Zehtabcheh S, Yousefi AM, Salari S, Safa M, Momeny M, Ghaffari SH, Bashash D (2021) Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K\/c-Myc axis on panobinostat cytotoxicity. Cell Biol Int 45(5):1111\u20131121","journal-title":"Cell Biol Int"},{"issue":"1","key":"8832_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","volume":"151","author":"CY Lin","year":"2012","unstructured":"Lin CY, Lov\u00e9n J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA (2012) Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151(1):56\u201367","journal-title":"Cell"},{"issue":"3","key":"8832_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/genes10030244","volume":"10","author":"L Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez L, Delgado MD, Le\u00f3n J (2019) MYC oncogene contributions to release of cell cycle brakes. Genes 10(3):244","journal-title":"Genes"},{"issue":"1","key":"8832_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-020-01291-6","volume":"20","author":"SK Madden","year":"2021","unstructured":"Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM (2021) Taking the myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer 20(1):1\u201318","journal-title":"Mol Cancer"},{"issue":"7607","key":"8832_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT (2016) Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 534(7607):341\u2013346","journal-title":"Nature"},{"issue":"39","key":"8832_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jncimonographs\/lgn004","volume":"2008","author":"D Levens","year":"2008","unstructured":"Levens D (2008) How the c-myc promoter works and why it sometimes does not. J Natl Cancer Inst Monogr 2008(39):41\u201343","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"20","key":"8832_CR13","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","volume":"18","author":"DM Miller","year":"2012","unstructured":"Miller DM, Thomas SD, Islam A, Muench D, Sedoris K (2012) c-Myc and cancer metabolism. Clin Cancer Res 18(20):5546\u20135553","journal-title":"Clin Cancer Res"},{"issue":"47","key":"8832_CR14","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","volume":"21","author":"S Xie","year":"2002","unstructured":"Xie S, Lin H, Sun T, Arlinghaus RB (2002) Jak2 is involved in c-Myc induction by bcr-abl. Oncogene 21(47):7137\u20137146","journal-title":"Oncogene"},{"issue":"6","key":"8832_CR15","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","volume":"107","author":"M Notari","year":"2006","unstructured":"Notari M, Neviani P, Santhanam R, Blaser BW, Chang J-S, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G (2006) A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation. Blood 107(6):2507\u20132516","journal-title":"Blood"},{"issue":"1","key":"8832_CR16","first-page":"68","volume":"31","author":"R Oudat","year":"2001","unstructured":"Oudat R, Khan Z, Glassman AB (2001) Detection of Trisomy 8 in Philadelphia chromosome\u2013positive CML Patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement. Annals of Clinical & Laboratory Science 31(1):68\u201374","journal-title":"Annals of Clinical & Laboratory Science"},{"key":"8832_CR17","doi-asserted-by":"crossref","unstructured":"Fletcher S, Prochownik EV (2015) Small-molecule inhibitors of the myc oncoprotein. Biochimica Et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 1849(5):525\u2013543","DOI":"10.1016\/j.bbagrm.2014.03.005"},{"key":"8832_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-014-0226-x","volume":"12","author":"J Wang","year":"2014","unstructured":"Wang J, Ma X, Jones HM, Chan LL-Y, Song F, Zhang W, Bae-Jump VL, Zhou C (2014) Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells. J Translational Med 12:1\u201311","journal-title":"J Translational Med"},{"key":"8832_CR19","doi-asserted-by":"publisher","first-page":"174345","DOI":"10.1016\/j.ejphar.2021.174345","volume":"908","author":"R Ghaffarnia","year":"2021","unstructured":"Ghaffarnia R, Nasrollahzadeh A, Bashash D, Nasrollahzadeh N, Mousavi SA, Ghaffari SH (2021) Inhibition of c-Myc using 10058-F4 induces anti-tumor effects in ovarian cancer cells via regulation of FOXO target genes. Eur J Pharmacol 908:174345","journal-title":"Eur J Pharmacol"},{"key":"8832_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.biopha.2015.05.019","volume":"73","author":"M Zhang","year":"2015","unstructured":"Zhang M, Fan H-Y, Li S-C (2015) Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma. Biomed Pharmacother 73:123\u2013128","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"8832_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/CAD.0b013e3280109424","volume":"18","author":"C-P Lin","year":"2007","unstructured":"Lin C-P, Liu J-D, Chow J-M, Liu C-R, Liu HE (2007) Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs 18(2):161\u2013170","journal-title":"Anticancer Drugs"},{"key":"8832_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00280-008-0774-y","volume":"63","author":"J Guo","year":"2009","unstructured":"Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV, Eiseman JL (2009) Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc\u2013Max disruptor, 10058-F4 [Z, E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol 63:615\u2013625","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"8832_CR23","doi-asserted-by":"publisher","first-page":"e97285","DOI":"10.1371\/journal.pone.0097285","volume":"9","author":"I M\u00fcller","year":"2014","unstructured":"M\u00fcller I, Larsson K, Frenzel A, Oliynyk G, Zirath H, Prochownik EV, Westwood NJ, Henriksson MA (2014) Targeting of the MYCN protein with small molecule c-MYC inhibitors. PLoS ONE 9(5):e97285","journal-title":"PLoS ONE"},{"issue":"26","key":"8832_CR24","doi-asserted-by":"publisher","first-page":"22698","DOI":"10.18632\/oncotarget.4245","volume":"6","author":"T Holien","year":"2015","unstructured":"Holien T, Misund K, Olsen OE, Baranowska KA, Buene G, B\u00f8rset M, Waage A, Sundan A (2015) MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy. Oncotarget 6(26):22698","journal-title":"Oncotarget"},{"issue":"7","key":"8832_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.leukres.2015.04.003","volume":"39","author":"M Cinar","year":"2015","unstructured":"Cinar M, Rosenfelt F, Rokhsar S, Lopategui J, Pillai R, Cervania M, Pao A, Cinar B, Alkan S (2015) Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas. Leuk Res 39(7):730\u2013738","journal-title":"Leuk Res"},{"issue":"5","key":"8832_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","volume":"9","author":"M Albajar","year":"2011","unstructured":"Albajar M, G\u00f3mez-Casares MT, Llorca J, Mauleon I, Vaqu\u00e9 JP, Acosta JC, Berm\u00fadez A, Donato N, Delgado MD, Le\u00f3n J (2011) MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to ImatinibMYC and Response to Imatinib in Chronic myeloid LeukemiaMYC and response to Imatinib in Chronic myeloid leukemia. Mol Cancer Res 9(5):564\u2013576","journal-title":"Mol Cancer Res"},{"issue":"1","key":"8832_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10142","volume":"22","author":"C Chen","year":"2021","unstructured":"Chen C, Gao H, Su X (2021) Autophagy-related signaling pathways are involved in cancer. Experimental and Therapeutic Medicine 22(1):1\u201313","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"1","key":"8832_CR28","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1038\/s41467-019-11568-0","volume":"10","author":"I Annunziata","year":"2019","unstructured":"Annunziata I, van de Vlekkert D, Wolf E, Finkelstein D, Neale G, Machado E, Mosca R, Campos Y, Tillman H, Roussel MF (2019) MYC competes with MiT\/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat. Nat Commun 10(1):3623","journal-title":"Nat Commun"},{"issue":"25","key":"8832_CR29","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1093\/hmg\/ddt381","volume":"22","author":"PP Toh","year":"2013","unstructured":"Toh PP, Luo S, Menzies FM, Rasko T, Wanker EE, Rubinsztein DC (2013) Myc inhibition impairs autophagosome formation. Hum Mol Genet 22(25):5237\u20135248","journal-title":"Hum Mol Genet"},{"key":"8832_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","volume":"14","author":"SE Ahmadi","year":"2021","unstructured":"Ahmadi SE, Rahimi S, Zarandi B, Chegeni R, Safa M (2021) MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. J Hematol Oncol 14:1\u201349","journal-title":"J Hematol Oncol"},{"issue":"16","key":"8832_CR31","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1038\/onc.2008.24","volume":"27","author":"Z Fu","year":"2008","unstructured":"Fu Z, Tindall D (2008) FOXOs, cancer and regulation of apoptosis. Oncogene 27(16):2312\u20132319","journal-title":"Oncogene"},{"issue":"11","key":"8832_CR32","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.bbamcr.2011.03.010","volume":"1813","author":"X Zhang","year":"2011","unstructured":"Zhang X, Tang N, Hadden TJ, Rishi AK, Akt (2011) FoxO and regulation of apoptosis. Biochim et Biophys Acta (BBA)-Molecular Cell Res 1813(11):1978\u20131986","journal-title":"Biochim et Biophys Acta (BBA)-Molecular Cell Res"},{"issue":"21","key":"8832_CR33","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1200\/JCO.2005.05.081","volume":"23","author":"A Mani","year":"2005","unstructured":"Mani A, Gelmann EP (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23(21):4776\u20134789","journal-title":"J Clin Oncol"},{"issue":"3","key":"8832_CR34","doi-asserted-by":"publisher","first-page":"C451","DOI":"10.1152\/ajpcell.00286.2019","volume":"318","author":"P Saavedra-Garc\u00eda","year":"2020","unstructured":"Saavedra-Garc\u00eda P, Martini F, Auner HW (2020) Proteasome inhibition in multiple myeloma: lessons for other cancers. Am J Physiology-Cell Physiol 318(3):C451\u2013C62","journal-title":"Am J Physiology-Cell Physiol"},{"issue":"4","key":"8832_CR35","first-page":"825","volume":"8","author":"H Oyaizu","year":"2001","unstructured":"Oyaizu H, Adachi Y, Okumura T, Okigaki M, Oyaizu N, Taketani S, Ikebukuro K, Fukuhara S, Ikehara S (2001) Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol Rep 8(4):825\u2013829","journal-title":"Oncol Rep"},{"issue":"19","key":"8832_CR36","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB (2021) Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers 13(19):4820","journal-title":"Cancers"},{"issue":"12","key":"8832_CR37","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.3390\/jcm9123865","volume":"9","author":"S Soverini","year":"2020","unstructured":"Soverini S, Bernardi S, Galimberti S (2020) Molecular testing in CML between old and new methods: are we at a turning point? J Clin Med 9(12):3865","journal-title":"J Clin Med"},{"issue":"6","key":"8832_CR38","doi-asserted-by":"publisher","first-page":"a014241","DOI":"10.1101\/cshperspect.a014241","volume":"4","author":"M Gabay","year":"2014","unstructured":"Gabay M, Li Y, Felsher DW (2014) MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harbor Perspectives in Medicine 4(6):a014241","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"issue":"8","key":"8832_CR39","doi-asserted-by":"publisher","first-page":"e202103090","DOI":"10.1083\/jcb.202103090","volume":"220","author":"JR Whitfield","year":"2021","unstructured":"Whitfield JR, Soucek L (2021) The long journey to bring a myc inhibitor to the clinic. J Cell Biol 220(8):e202103090","journal-title":"J Cell Biol"},{"key":"8832_CR40","doi-asserted-by":"crossref","unstructured":"Wu S-X, Xiong R-G, Huang S-Y, Zhou D-D, Saimaiti A, Zhao C-N, Shang A, Zhang Y-J, Gan R-Y, Li H-B (2022) Effects and mechanisms of resveratrol for prevention and management of cancers: an updated review. Crit Rev Food Sci Nutr. :1\u201319","DOI":"10.1080\/10408398.2022.2101428"},{"issue":"8","key":"8832_CR41","doi-asserted-by":"publisher","first-page":"14004","DOI":"10.1002\/jcb.28675","volume":"120","author":"N Sheikh-Zeineddini","year":"2019","unstructured":"Sheikh-Zeineddini N, Bashash D, Safaroghli\u2010Azar A, Riyahi N, Shabestari RM, Janzamin E, Safa M (2019) Suppression of c\u2010Myc using 10058\u2010F4 exerts caspase\u20103\u2010dependent apoptosis and intensifies the antileukemic effect of vincristine in pre\u2010B acute lymphoblastic leukemia cells. J Cell Biochem 120(8):14004\u201314016","journal-title":"J Cell Biochem"},{"issue":"6","key":"8832_CR42","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3892\/ol.2014.2553","volume":"8","author":"I Ninomiya","year":"2014","unstructured":"Ninomiya I, Yamazaki K, Oyama K, Hayashi H, Tajima H, Kitagawa H, Fushida S, Fujimura T, Ohta T (2014) Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Oncol Lett 8(6):2709\u20132714","journal-title":"Oncol Lett"},{"issue":"3","key":"8832_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/1541-7786.MCR-11-0394","volume":"10","author":"LC Spender","year":"2012","unstructured":"Spender LC, Inman GJ (2012) Phosphoinositide 3-kinase\/AKT\/mTORC1\/2 signaling determines sensitivity of Burkitt\u2019s lymphoma cells to BH3 mimeticsPI3K\/mTOR inhibition overcomes resistance of BL to ABT-737. Mol Cancer Res 10(3):347\u2013359","journal-title":"Mol Cancer Res"},{"key":"8832_CR44","doi-asserted-by":"publisher","first-page":"105734","DOI":"10.1016\/j.biocel.2020.105734","volume":"122","author":"M Mosleh","year":"2020","unstructured":"Mosleh M, Safaroghli-Azar A, Bashash D (2020) Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: an emerging approach to overcome MSC-induced resistance. Int J Biochem Cell Biol 122:105734","journal-title":"Int J Biochem Cell Biol"},{"issue":"13","key":"8832_CR45","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.onc.1210823","volume":"27","author":"H Wang","year":"2008","unstructured":"Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas M, Gudkov A, Prochownik E, Nikiforov M (2008) c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene 27(13):1905\u20131915","journal-title":"Oncogene"},{"issue":"1","key":"8832_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13045-020-01000-2","volume":"13","author":"H Chang","year":"2020","unstructured":"Chang H, Zou Z (2020) Targeting autophagy to overcome drug resistance: further developments. J Hematol Oncol 13(1):159","journal-title":"J Hematol Oncol"},{"key":"8832_CR47","doi-asserted-by":"crossref","unstructured":"Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJL, Lam EW-F, Burgering BM, Medema RH (2002) Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Molecular and cellular biology. 22(22):7842\u20137852","DOI":"10.1128\/MCB.22.22.7842-7852.2002"},{"issue":"5\u20136","key":"8832_CR48","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1089\/ars.2005.7.752","volume":"7","author":"Y Furukawa-Hibi","year":"2005","unstructured":"Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N (2005) FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 7(5\u20136):752\u2013760","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"8832_CR49","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2174\/156652412800619978","volume":"12","author":"E Tamura","year":"2012","unstructured":"Tamura E, de Vasconcellos RF, Sarkar J, Libermann DA, Fisher TB (2012) F Zerbini L. GADD45 proteins: central players in tumorigenesis. Curr Mol Med 12(5):634\u2013651","journal-title":"Curr Mol Med"},{"key":"8832_CR50","doi-asserted-by":"crossref","unstructured":"Sharpe JC, Arnoult D, Youle RJ (2004) Control of mitochondrial permeability by Bcl-2 family members. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 1644(2\u20133):107\u2013113","DOI":"10.1016\/j.bbamcr.2003.10.016"},{"key":"8832_CR51","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2021-151315","volume":"138","author":"A Catic","year":"2021","unstructured":"Catic A, Maneix L, Iakova P, Mistry R, Stossi F, Yellapragada SV, Lulla PD (2021) Epigenetic silencing of MYC by Proteasome inhibitors. Blood 138:2212","journal-title":"Blood"},{"issue":"7","key":"8832_CR52","doi-asserted-by":"publisher","first-page":"e6257","DOI":"10.1371\/journal.pone.0006257","volume":"4","author":"Z Hu","year":"2009","unstructured":"Hu Z, Pan X-F, Wu F-Q, Ma L-Y, Liu D-P, Liu Y, Feng T-T, Meng F-Y, Liu X-L, Jiang Q-L (2009) Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS ONE 4(7):e6257","journal-title":"PLoS ONE"},{"issue":"2","key":"8832_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.18632\/oncotarget.1643","volume":"5","author":"H Huang","year":"2014","unstructured":"Huang H, Ma L, Li J, Yu Y, Zhang D, Wei J, Jin H, Xu D, Gao J, Huang C (2014) NF-\u03baB1 inhibits c-Myc protein degradation through suppression of FBW7 expression. Oncotarget 5(2):493","journal-title":"Oncotarget"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08832-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08832-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08832-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T17:04:21Z","timestamp":1700931861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08832-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,4]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["8832"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08832-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"type":"print","value":"0301-4851"},{"type":"electronic","value":"1573-4978"}],"subject":[],"published":{"date-parts":[[2023,11,4]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}